Introduction
============

Previous studies have, demonstrate that immune cell infiltration in human gastrointestinal cancers is associated with cancer progression and is a favorable prognostic predictor ([@b1-ol-0-0-11828]--[@b5-ol-0-0-11828]). Both cellular composition and organization of tumor infiltrating lymphocytes (TILs) are crucial for inhibiting cancer progression and are implicated in the success of cancer immunotherapy ([@b1-ol-0-0-11828],[@b2-ol-0-0-11828],[@b6-ol-0-0-11828]). Tertiary lymphoid structure (TLSs) are an important source of TILs, characterized by ectopic aggregated lymphocytes with high endothelial venules and have a similar function to secondary lymphoid organs (SLOs). The lymphocytes in TLSs have easy access to tumor antigens as TLSs are not encapsulated and embedded within the tumor microenvironment ([@b5-ol-0-0-11828]). The numbers of both TILs and TLSs within solid tumor tissues can be used for the assessment of tumor immune surveillance and are important prognostic factors for cancer ([@b7-ol-0-0-11828]--[@b11-ol-0-0-11828]).

Although TLSs are thought to be associated with anti-tumor immune responses ([@b12-ol-0-0-11828]--[@b15-ol-0-0-11828]), the functional role of their cellular components remains unclear. TLSs are divided into B- and T-zones, which consist of follicular dendritic cells (FDCs) and fibroblastic reticular cells (FRCs), respectively ([@b16-ol-0-0-11828]). TLSs can be further defined as primary and secondary TLSs, based on the absence or presence of a germinal center in B-cell follicles. Following stimulation by tumor antigens, B cells differentiate and form the germinal center, which is the site of B cell proliferation, class switching and somatic hyper mutation ([@b17-ol-0-0-11828]--[@b19-ol-0-0-11828]). CD4^+^ CXCR5^+^ T follicular helper (Tfh) cells are a subtype of CD4^+^ helper T cells, principally located in germinal centers, and play critical roles in recruiting, activating and regulating the germinal center ([@b20-ol-0-0-11828]--[@b22-ol-0-0-11828]). Previous studies suggested that Tfh cells mediate follicular and germinal center formation in TLSs ([@b23-ol-0-0-11828],[@b24-ol-0-0-11828]). In recent studies, CXCR5^+^ CD8^+^ T cells were found within the lymphoid follicle, primarily within the germinal center, where they controlled viral replication during chronic HIV and lymphocytic choriomeningitis virus (LMCV) infection ([@b25-ol-0-0-11828],[@b26-ol-0-0-11828]). The CD20^+^ B cells and CD8^+^ T cells co-localize in the tumor nest ([@b20-ol-0-0-11828]) and TLSs ([@b21-ol-0-0-11828]). This distribution pattern of follicular CD8^+^ T cells might be involved in antitumor immune responses.

The present study investigated follicular CD8^+^ T cells in the tumor tissues of patients with gastric cancer (GC). In addition, germinal center CD8^+^ (gcCD8^+^) TILs were quantified. The relationship between tumoral immune parameters such as TILs, TLSs, TILs-TLSs and gcCD8^+^ TILs and clinical pathological parameters was determined.

Materials and methods
=====================

### Patients and tissue samples

The present study retrospectively analyzed data of patients admitted to the Department of Pathology, Third Affiliated Hospital of Soochow University between 2006 to 2008. The patients were enrolled according to the following criteria: i) Pathologically-confirmed diagnosis of primary GC (adenocarcinoma); ii) did not receive pre-operative chemotherapy or radiotherapy; iii) presence of adequate paraffin-embedded fixed tissue blocks; iv) at least one slide contained the invasive margin of the tumor; and v) availability of complete medical records and follow-up information. A total of 63 patients with GC were included in this present study. Tumor clinical and pathological staging system was based on the Eighth Edition of the Union for International Cancer Control/American Joint Committee on Cancer. Three slides contain cancer tissue were available for each patient, and a total of 189 slides were reviewed in the present study. Patient survival data were available until the end of November 2011. Patient clinical data are presented in [Table I](#tI-ol-0-0-11828){ref-type="table"}. The present study was approved by the Ethics Committee of Soochow University, and complied with the Declaration of Helsinki. Informed consent to use the tissue sample for scientific research was obtained from all patients.

### Pathomorphological evaluation of TILs and TLSs

Cancer tissue was fixed in 10% (v/v) formalin and embedded in paraffin until use. The H&E stained slides of the resected GC tissues were reviewed and scored independently by two pathologists who were blinded to the clinical data and prognosis of the patients. The pathologists were trained in the pathomorphological evaluation of TILs and TLSs, and any problematic cases were discussed with them during subsequent scoring. The TILs and TLSs in the center of the tumor (CT) and the invasive margin (IM) were examined ([@b11-ol-0-0-11828],[@b27-ol-0-0-11828],[@b28-ol-0-0-11828]). The TILs scoring system incorporated two aspects: i) The number of infiltrating lymphocytes; score 0, no infiltration; score 1, mild infiltration; score 2, moderate infiltration; score 3, extensive infiltration ([Fig. 1](#f1-ol-0-0-11828){ref-type="fig"}); and ii) the percentage of the tumor area containing TILs in the CT or IM. The CT-TILs and IM-TILs location scores were defined as the number of infiltrating lymphocytes multiplied by the percentage, and then, the final score was computed by summation of the CT- and IM-TILs scores. TLSs were also evaluated in the CT and IM by measuring two factors: The number of TLSs (aggregates of lymphocytes with and without germinal centers were counted) and the percentage, similar to the TILs, in the CT or IM ([@b29-ol-0-0-11828],[@b30-ol-0-0-11828]). The CT-TLSs and IM-TLSs location scores were defined as the numbers multiplied by the percentage, and then, the final score of TLSs was computed by summation of the CT- and IM-TLS scores.

### Immunohistochemistry and evaluation of the gcCD8^+^ T cells

Formalin-fixed and paraffin-embedded (FFPE) tissues were cut into 4 µm thick consecutive sections deparaffinized in xylene and rehydrated in graded ethanol solutions. Monoclonal mouse antibody against human CD8 (MAB-0021, ready to use, Maixin Biotechnology Limited Corporation) was used to stain the T lymphocytes. The CD8 antigen was retrieved by boiling the slides in citrate buffer (10 mmol/l; pH 6.0) under high pressure for 2 min. Then, the sections were immersed in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity, rinsed three times in PBS, and then incubated with primary antibodies at 4°C overnight. The negative control was performed with PBS. The sections were incubated with horseradish peroxidase-labeled goat anti-mouse secondary antibody (ready to use, Maixin Biotechnology Limited Corporation). Diaminobenzene was used as the chromogen and hematoxylin as the nuclear counterstain. The scoring system for gcCD8^+^ TILs was assessed in every slide. The number of germinal centers and gcCD8^+^ TILs in each germinal center were counted. The average values were subsequently obtained.

### Statistical analysis

Statistical analyses were performed using SPSS (version 24.0; IBM Corp.) and GraphPad Prism software (version 6; GraphPad Software, Inc.). Data were analyzed using the χ^2^ test, Kaplan-Meier method and Cox regression analysis as appropriate. All tests were two-sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Relationship between tumoral immune parameters and clinical pathological parameters

The TILs, TLSs, and gcCD8^+^ TILs were defined as tumoral immune parameters in the present study ([Tables I](#tI-ol-0-0-11828){ref-type="table"} and [II](#tII-ol-0-0-11828){ref-type="table"}). In order to make the scoring system more facilitative to statistical analysis, these variables were converted into binary variables. TILs were sub-grouped by the TIL final score: TIL^hi^ 44 cases, score \>0.45 \[area under the receiver operating characteristic curve (AUC)=0.35; sensitivity, 82.1%; specificity, 50.0%\], and TIL^low^ 19 cases, score ≤0.45 ([Table I](#tI-ol-0-0-11828){ref-type="table"}; [Fig. 1A-C](#f1-ol-0-0-11828){ref-type="fig"}). TLSs were sub-grouped by the TLS final score: TLS^hi^ 43 cases, score \>0.42 (AUC=0.39; sensitivity, 79.5%; specificity, 50.0%), and TLS^low^ 20 cases, score ≤0.42 ([Table I](#tI-ol-0-0-11828){ref-type="table"}; [Fig. 1D-F](#f1-ol-0-0-11828){ref-type="fig"}). Considering the combination of TILs and TLSs, the samples were divided into two groups. The TIL-TLS^hi^ group (32 cases) consisted of samples that scored as both TIL^hi^ and TLS^hi^. The TIL-TLS^low^ group (31 cases) consisted of samples that scored as TIL^hi^-TLS^low^, TIL^low^-TLS^hi^ and TIL^low^-TLS^low^ ([Table I](#tI-ol-0-0-11828){ref-type="table"}). Based on the density of gcCD8^+^ TILs, 55 samples (specimens from eight cases were excluded due to absence of germinal centers) were divided into two groups: gcCD8^hi^ TIL, 23 cases, score \>6.93 (AUC=0.19; sensitivity, 59.5%; specificity, 94.4%; [Fig. 2A-F](#f2-ol-0-0-11828){ref-type="fig"}), and gcCD8^low^ TIL, 32 cases, score ≤6.93 ([Table I](#tI-ol-0-0-11828){ref-type="table"}; [Fig. 2G-L](#f2-ol-0-0-11828){ref-type="fig"}).

The TILs were significantly associated with the tumor size, nerve invasion, lymph nodal metastasis, histological grade and pTN stage (P=0.007, 0.001, 0.004, 0.026 and 0.018, respectively; [Table II](#tII-ol-0-0-11828){ref-type="table"}). The data showed that the TLSs were not significantly associated with clinical pathological parameters. The combination of TILs-TLSs was significantly associated with nerve invasion, tumor thrombus, lymph nodal metastasis and histological grade (P=0.003, 0.006, 0.029 and 0.016, respectively; [Table II](#tII-ol-0-0-11828){ref-type="table"}). The data also showed the gcCD8^+^ TILs was significantly associated with patient age, histological grade and pTN stage (P=0.028, 0.010 and 0.048, respectively; [Table II](#tII-ol-0-0-11828){ref-type="table"}). The higher levels of gcCD8^+^ TILs were associated with lower histological grade and lower pTN stage. These data suggested that the gcCD8^+^ TILs might be involved in antitumor immunity in GC.

### Association between tumoral immune parameters and patient prognosis

Kaplan-Meier survival analysis showed that the patients with TIL^hi^, TLS^hi^, TIL-TLS^hi^ or gcCD8^hi^ TIL had favorable prognosis than those with lower levels (P=0.0008, 0.0108, 0.0005 and 0.0003, respectively; [Fig. 3A-D](#f3-ol-0-0-11828){ref-type="fig"}). The prognostic value of tumoral immune parameters in patients with advanced GC (pTN III stage) was investigated. The patients in the TIL-TLS^hi^ and gcCD8^hi^ TIL groups had an improved overall survival (OS) compared with patients in the TIL-TLS^low^ and gcCD8^low^ TIL groups (P=0.012 and 0.002; [Table III](#tIII-ol-0-0-11828){ref-type="table"}; [Fig. 3G and H](#f3-ol-0-0-11828){ref-type="fig"}).

In the univariate Cox regression analysis (analysis^a^), smaller tumor size, lower histological grade, absence of tumor thrombus or lymph nodal metastasis, lower pTN stage and higher levels of tumoral immune parameters were favorable prognostic factors for OS ([Table IV](#tIV-ol-0-0-11828){ref-type="table"}). Considering the possible interference among TILs, TLSs and TILs-TLSs, we did a cohort of multivariate Cox regression analysis. Multivariate Cox regression analysis^b^ (based on the clinicopathological feature, TILs, TLSs and gcCD8^+^ TILs) revealed that the gcCD8^+^ TILs were the only independent prognostic factor for OS (HR=0.087; 95% CI: 0.011--0.692; P=0.021; [Table IV](#tIV-ol-0-0-11828){ref-type="table"}). Multivariate Cox regression analysis^c^ (based on the clinicopathological feature, TILs-TLSs and gcCD8^+^ TILs) demonstrated that TILs-TLSs and gcCD8^+^ TILs were independent prognostic factors (HR=0.247, 95% CI: 0.069--0.882, P=0.031; HR=0.067, 95% CI: 0.008--0.561, P=0.013, respectively). Moreover, the multivariate Cox regression analysis^d^ was designed to determine the association between tumoral immune parameters (TILs, TLSs and gcCD8^+^ TILs). The result showed TILs and gcCD8^+^ TILs could be used as independent prognostic factors (HR=0.322, 95% CI: 0.124--0.835, P=0.020; HR=0.059, 95% CI: 0.008--0.451, P=0.006, respectively). The tumoral immune parameters exhibited an HR \<1 in the Cox regression analysis, suggesting that may protect against tumor progression.

Discussion
==========

The present study demostrated that patients with GC with higher levels of TILs, or TLSs, or gcCD8^+^ TILs had an improved OS. Multivariate Cox regression analysis revealed that TILs-TLSs and gcCD8^+^ TILs were independent prognostic factors. In addition, gcCD8^+^ TILs were significantly associated with patient age, histological grade and pTN stage. Higher levels of TILs-TLSs was positively associated with the nerve invasion, tumor thrombus, lymph nodal metastasis and histological grade. The data obtained in the present study suggested that high levels of tumoral immune parameters were associated with improved prognosis in patients with GC.

Cancer progression is a multi-step process that involves genetic, epigenetic, as well as histopathological change ([@b3-ol-0-0-11828],[@b31-ol-0-0-11828]--[@b33-ol-0-0-11828]). Infiltrating immune cells play an important role in preventing or promoting cancer progression ([@b34-ol-0-0-11828]). Previous studies have demonstrated that high levels of TILs may inhibit the progression of breast and colorectal cancer ([@b8-ol-0-0-11828],[@b31-ol-0-0-11828],[@b35-ol-0-0-11828]). The present study revealed that a high level of TILs was associated with improved prognosis in patient with GC. Univariate and multivariate Cox regression analyses revealed that TILs could be used as an independent favorable prognostic factor.

Previous studies demonstrated that TLSs are required for the development of the T- and B-cell mediated immune response against human cancer and various other diseases ([@b25-ol-0-0-11828],[@b26-ol-0-0-11828],[@b31-ol-0-0-11828],[@b36-ol-0-0-11828],[@b37-ol-0-0-11828]). TLSs have been previously described in several types of cancer, such as lung cancer and breast cancer, and are associated with patient prognosis ([@b10-ol-0-0-11828],[@b17-ol-0-0-11828],[@b29-ol-0-0-11828]). TLSs are organization by heterotopic lymphoid tissues, and exhibit similar organization and functionality to SLOs. The basic components of TLSs include the T-zone, comprising of T cells and FRCs, and the B-zone, comprising of B cells and FDCs. TLSs are involved in establishing a systemic memory response to protect patients against circulating metastatic cancer cells, therefor inhibiting tumor recurrence for several years ([@b8-ol-0-0-11828],[@b31-ol-0-0-11828]). The present study revealed that the high levels of TLSs were associated with improved outcome in patients with GC, and could therefor be used as an independent prognostic factor. The combination of TILs and TLSs is superior to TILs or TLSs alone for predicting survival. In advanced cancer, the high levels of TILs-TLSs were associated with improved OS. Based on the results obtained in the present study, TLSs are an important niche in which tumor antigen specific T and B cells are generated.

Despite the association of gcCD8^+^ T cells with improved prognosis, the role of gcCD8^+^ T cells in antitumor immune responses and germinal center B cell responses remains unknow. Previous studies investigating chronic infection with LMCV and HIV revealed that there are two subsets of CD8^+^ effector T cells, namely CXCR5^+^ PD-1^+^ CD8^+^ T and CXCR5^−^ PD-1^+^ CD8^+^ T cells ([@b26-ol-0-0-11828],[@b38-ol-0-0-11828]). The CXCR5^+^ subset exhibits stem cell-like properties and is localized in the B cell follicle and germinal center during chronic infection. The CXCR5^+^ subset undergo self-renewal and can differentiate into CXCR5^−^ CD8^+^ T cells. The *de novo* converted CXCR5^−^ subset exhibits increased cytotoxicity and removes virus infected cells. Hornquist *et al* ([@b39-ol-0-0-11828]) studied the role of CD8^+^ T cells in the regulation of gut mucosal immune responses and showed that CD8^+^ T cells inhibited local B cell responses. By contrast, B cells and plasma cells have been shown to impede T cell-mediated antitumor immune responses ([@b40-ol-0-0-11828]--[@b42-ol-0-0-11828]). Based on the aforementioned findings, gcCD8^+^ T cells are likely to promote cell-mediate antitumor immune responses and inhibit humoral immunity. A diagrammatic representation based on two hypotheses is presented in [Fig. S1](#SD1-ol-0-0-11828){ref-type="supplementary-material"}. Based on the results obtained from studies investigating chronic HIV or LMCV infection ([@b43-ol-0-0-11828],[@b44-ol-0-0-11828]), it is hypothesized that PD1^+^ CD8^+^ TILs may be further divided into CXCR5^+^ and CXCR5^−^ subsets, which are regulated by the inhibitor of DNA binding 2 (ID2)/transcription factor E2-α axis. The CXCR5^+^ subset located in the B cell follicle and the germinal center. The follicular CXCR5^+^ CD8^+^ T cells subset can undergo proliferation and differentiate into the CXCR5^−^ subset following ID2 upregulation. 2. According to the studies by Hornquist *et al* ([@b39-ol-0-0-11828]) and Li *et al* ([@b44-ol-0-0-11828]), germinal center CXCR5^+^ CD8^+^ T cells can exert a suppressive effect on germinal B cell responses and inhibit the generation of plasma cells. Some mechanisms in these hypotheses were demonstrated. Elimination of immunosuppressive B cells expressing IgA, IL-10 and PD-L1 allows CD8^+^ cytotoxic T cells eradication of oxaliplatin-resistance prostate cancer ([@b40-ol-0-0-11828]). The expression of CXCR5 on CD8^+^ T cells was necessary for T cells infiltrating into B-cells follicular ([@b43-ol-0-0-11828]). The present study revealed that the phenotype of TILs, TLSs and gcCD8^+^ TILs exhibited significant heterogeneity in patients with GC. TILs, TLSs and gcCD8^+^ TILs may be had the potential function associated with GC immunotherapy. Further investigation is required to validate the hypotheses proposed in the present study.
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![Pathomorphological images of inflammatory cell reactions in gastric cancer. (A) Low and (B and C) high levels of tumor infiltrating lymphocytes. Magnification, ×200; scale bar, 50 µm. Tertiary lymphoid structures (marked with blue arrows) in different gastric anatomical layers: (D) In the mucosa, (E) in the submucosa and (F) in the muscularis propria. Magnification, ×100; scale bar, 100 µm.](ol-20-03-2655-g00){#f1-ol-0-0-11828}

![Two cases of (A-F) gcCD8^hi^ TILs and (G-L) gcCD8^low^ TILs were presented. (A) Case 1 had the TLS with a follicle and germinal center (marked with blue arrow) in HE slides. (B) CD20 staining revealed B lymphocyte aggregation and the germinal center. (C) CD21 staining revealed the follicular dendritic cell network in the germinal center. (D) Enlarged images of the red square area revealed follicular CD8^+^ TILs around the germinal center. (E and F) gcCD8^+^ TILs were detected in the germinal center (red arrows). (G) TLS marked with a blue arrow were also observed in Case 2. (H-J) The same expression pattern of CD20, CD21 and CD8 was observed. (K-L) Conversely, there were no gcCD8^+^ TILs that infiltrated into the germinal center. (A-D and G-J) Magnification, ×100; scale bar, 100 µm. (E and K) Magnification, ×200; scale bar, 50 µm. (F and L) Magnification, ×400; scale bar, 20 µm. TLS, tertiary lymphoid structure; CD, cluster of differentiation; HE, hematoxylin and eosin; TILs, tumor infiltrating lymphocytes.](ol-20-03-2655-g01){#f2-ol-0-0-11828}

![Kaplan-Meier survival curves for tumoral immune parameters. Kaplan-Meier analysis of overall survival for 63 patients stratified by (A) TILs, (B) TLSs and (C) TILs-TLSs in gastric cancer, and for 55 patients stratified by (D) gcCD8^+^ TILs. In pTN III stage, there was no statistically significant difference between the (E) IL or (F) TLS levels and OS. However, patients with high levels of (G) TILs-TLSs and (H) gcCD8 TILs had an improved OS. TILs, tumor infiltrating lymphocytes; TLSs, tertiary lymphoid structures; OS, overall survival.](ol-20-03-2655-g02){#f3-ol-0-0-11828}

###### 

Details of parameters in the study cohort.

                                                                Total study cohort   
  ------------------------------------------------------------- -------------------- ------
  Sex                                                                                
    Male                                                        49                   77.8
    Female                                                      14                   22.2
  Age, years                                                                         
    ≤50                                                         8                    12.7
    \>50                                                        55                   87.3
  Tumor size                                                                         
    ≤5 cm                                                       39                   61.9
    \>5 cm                                                      24                   38.1
  Nerve invasion                                                                     
    Yes                                                         25                   39.7
    No                                                          38                   60.3
  Tumor thrombus                                                                     
    Yes                                                         22                   34.9
    No                                                          41                   65.1
  Nodal metastasis                                                                   
    Yes                                                         36                   57.1
    No                                                          27                   42.9
  Histological grade                                                                 
    I--II                                                       30                   47.6
    III                                                         33                   52.4
  pTN stage                                                                          
    I                                                           23                   36.5
    II                                                          13                   20.6
    III                                                         27                   42.9
  TILs                                                                               
    High                                                        44                   69.8
    Low                                                         19                   30.2
  TLSs                                                                               
    High                                                        43                   68.3
    Low                                                         20                   31.7
  TILs and TLSs                                                                      
    High                                                        32                   50.8
    Low                                                         31                   49.2
  gcCD8^+^ TILs^[a](#tfn1-ol-0-0-11828){ref-type="table-fn"}^                        
    High                                                        23                   41.8
    Low                                                         32                   58.2

gcCD8^+^ TILs were obtained in 55 patients. TILs, tumor infiltrating lymphocytes; TLSs, tertiary lymphoid structures.

###### 

Association between clinicopathological parameters and tumoral immune parameters.

                       gcCD8^+^ TILs                TILs                  TLSs                        TILs-TLSs                                     
  -------------------- --------------- ---- ------- ----------- ---- ---- -------- ------------- ---- ----------- ------- ------- ---- ---- ------- -----------
  Sex                                                                                                                                               
    Male               23              19   0.854   0.355       17   32   2.153    0.142         15   34          0.131   0.718   26   23   1.311   0.252
    Female             9               4                        2    12                          5    9                           5    9            
  Age (years)                                                                                                                                       
    ≤50                6               0    4.841   **0.028**   4    4    1.713    0.191         3    5           0.140   0.708   5    3    0.648   0.421
    \>50               26              23                       15   40                          17   38                          26   29           
  Tumor size                                                                                                                                        
    ≤5 cm              18              17   1.804   0.179       7    32   7.246    **0.007**     12   27          0.045   0.832   16   23   2.741   0.098
    \>5 cm             14              6                        12   12                          8    16                          15   9            
  Nerve invasion                                                                                                                                    
    Yes                12              8    0.043   0.836       14   11   13.140   **\<0.001**   10   15          1.303   0.254   18   7    8.616   **0.003**
    No                 20              15                       5    33                          10   28                          13   25           
  Tumor thrombus                                                                                                                                    
    Yes                13              4    3.383   0.066       10   12   3.755    0.053         10   12          2.932   0.087   16   6    7.483   **0.006**
    No                 19              19                       9    32                          10   31                          15   26           
  Nodal metastasis                                                                                                                                  
    Yes                20              9    2.932   0.087       16   20   8.139    **0.004**     12   24          0.098   0.755   22   14   4.763   **0.029**
    No                 12              14                       3    24                          8    19                          9    18           
  Histological grade                                                                                                                                
    I--II              11              16   6.631   **0.010**   5    25   4.950    **0.026**     8    22          0.682   0.409   10   20   5.773   **0.016**
    III                21              7                        14   19                          12   21                          21   12           
  pTN stage                                                                                                                                         
    I                  9               13   6.053   **0.048**   2    21   8.072    **0.018**     6    17          0.642   0.725   7    16   5.399   0.067
    II                 6               5                        5    8                           5    8                           7    6            
    III                17              5                        12   15                          9    18                          17   10           

Values in bold indicate P\<0.05. TILs, tumor infiltrating lymphocytes; TLSs, tertiary lymphoid structures.

###### 

Kaplan-Meier analysis of tumoral immune parameters.

  A, Tumoral immune parameters in all cases                                                                                                
  --------------------------------------------------------- -------------- --------------------- --------------------- ------------------- -------------
  TILs                                                                                                                                     
    High                                                    44             12                    49.25                 11.198              **0.001**
    Low                                                     19             12                    24.21                                     
  TLSs                                                                                                                                     
    High                                                    43             12                    48.14                 6.501               **0.011**
    Low                                                     20             12                    33.40                                     
  TILs-TLSs                                                                                                                                
    High                                                    32             6                     53.03                 12.148              **\<0.001**
    Low                                                     31             18                    33.42                                     
  gcCD8^+^ TILs                                                                                                                            
    High                                                    23             1                     57.83                 13.322              **\<0.001**
    Low                                                     32             17                    36.16                                     
                                                                                                                                           
  **B, Tumoral immune parameters in pTN III stage cases**                                                                                  
                                                                                                                                           
  **Parameters**                                            **Cases, n**   **Status of death**   **Mean OS, months**   **Log-Rank χ^2^**   **P-value**
                                                                                                                                           
  TILs                                                                                                                                     
    High                                                    12             10                    30.33                 3.527               0.06
    Low                                                     15             10                    18.58                                     
  TLSs                                                                                                                                     
    High                                                    18             11                    19.11                 3.089               0.079
    Low                                                     9              9                     18.89                                     
  TILs-TLSs                                                                                                                                
    High                                                    10             5                     35.50                 6.310               **0.012**
    Low                                                     17             15                    19.00                                     
  gcCD8^+^ TILs                                                                                                                            
    High                                                    5              0                     --                    9.334               **0.002**
    Low                                                     17             15                    18.65                                     

Values in bold indicate P\<0.05. TILs, tumor infiltrating lymphocytes; TLSs, tertiary lymphoid structures.

###### 

Univariate and multivariate Cox regression analyses of clinicopathological parameters and tumoral immune parameters.

  A, Univariate analysis                                                                              
  --------------------------------------------- --------------------------- -------- ---------------- -------------
  Sex                                           Male/Female                 0.863    0.343--2.176     0.755
  Age, years                                    ≤50/\>50                    0.747    0.255--2.187     0.594
  Tumor size, cm                                ≤5/\>5                      3.643    1.587--8.363     **0.002**
  Histological grade                            I--II/III                   4.624    1.722--12.421    **0.002**
  Neural Invasion                               No/Yes                      2.168    0.969--4.847     0.060
  Tumor thrombus                                No/Yes                      6.619    2.716--16.134    **0.001**
  Lymphatic metastasis                          No/Yes                      11.528   2.702--49.184    **0.001**
  pTN stage                                     I--II/III                   18.732   2.525--138.976   **0.004**
  TILs                                          High/Low                    0.279    0.125--0.623     **0.002**
  TLSs                                          High/Low                    0.370    0.166--0.825     **0.015**
  gcCD8^+^ TILs                                 High/Low                    0.062    0.008--0.470     **0.007**
  TILs-TLSs                                     High/Low                    0.376    0.222--0.636     **0.000**
                                                                                                      
  **B, Multivariate Cox regression analysis**                                                         
  **Variables**                                 **Unfavorable/favorable**   **HR**   **95% CI**       **P-value**
                                                                                                      
  Tumor size, cm                                ≤5/\>5                      0.896    0.198--4.046     0.886
  Histological grade                              I--II/III                 1.009    0.277--3.671     0.990
  Tumor thrombus                                No/Yes                      2.227    0.482--10.748    0.299
  Lymphatic metastasis                          No/Yes                      1.251    0.135--11.560    0.844
  pTN stage                                     I--II/III                   5.594    0.336--93.237    0.230
  TILs                                          High/Low                    0.503    0.169--1.492     0.215
  TLSs                                          High/Low                    0.609    0.203--1.831     0.377
  gcCD8^+^ TILs                                 High/Low                    0.087    0.011--0.692     **0.021**
                                                                                                      
  **C, Multivariate Cox regression analysis**                                                         
                                                                                                      
  **Variables**                                 **Unfavorable/favorable**   **HR**   **95% CI**       **P-value**
                                                                                                      
  Tumor size, cm                                ≤5/\>5                      1.208    0.273--5.355     0.803
  Histological grade                            I--II/III                   0.806    0.208--3.116     0.754
  Tumor thrombus                                No/Yes                      1.742    0.381--7.970     0.474
  Lymphatic metastasis                          No/Yes                      0.980    0.103--9.296     0.986
  pTN stage                                     I--II/III                   7.159    0.419--122.410   0.174
  gcCD8^+^ TILs                                 High/Low                    0.067    0.008--0.561     **0.013**
  TILs-TLSs                                     High/Low                    0.247    0.069--0.882     **0.031**
                                                                                                      
  **D, Multivariate Cox regression analysis**                                                         
                                                                                                      
  **Variables**                                 **Unfavorable/favorable**   **HR**   **95% CI**       **P-value**
                                                                                                      
  TILs                                          High/Low                    0.322    0.124--0.835     **0.020**
  TLSs                                          High/Low                    0.396    0.148--1.056     0.064
  gcCD8^+^ TILs                                 High/Low                    0.059    0.008--0.451     **0.006**

Values in bold indicate P\<0.05. TILs, tumor infiltrating lymphocytes; TLSs, tertiary lymphoid structures; HR, hazard ratio.

[^1]: Contributed equally
